< Back to previous page
Researcher
Isabelle Huys
- Disciplines:Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Faculty of Law and Criminology (Faculty)
Member
From1 Oct 2014 → 30 Sep 2015 - Clinical Pharmacology and Pharmacotherapy (Division)
Member
From1 Jul 2013 → Today - Toxicology and Pharmacology (Division)
Member
From1 Oct 1999 → 9 Mar 2004
Projects
1 - 10 of 66
- 3D printed gastroretentive dosage forms for timed multidrug release (3Dose)From1 Oct 2025 → TodayFunding: IOF - technology validation in lab
- Patient-centred decision-making for rare diseasesFrom1 Oct 2025 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Big data and small farmers: The European agricultural data space confronted with smallholder knowledge practices.From1 Oct 2025 → TodayFunding: BOF - postdoctoral mandates
- A patient-informed clinical platform to inform patient-centered decision-making for rare diseases (INFORM-RD)From1 Oct 2025 → TodayFunding: Fund Recuperation Fiscal Exemption
- Stakeholder Engagement & Regulatory Frameworks in Patient-Centred EvidenceFrom16 Sep 2025 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- PUBLIC ENGAGEMENT IN RESEARCH INFRASTRUCTURES FOR MISSION CANCER: MANAGING COMPLEXITY OF EMERGING TECHNOLOGIESFrom1 Sep 2025 → TodayFunding: HORIZON.2.1 - Health
- ESTIMAND FRAMEWORK INVOLVING BAYESIAN PRINCIPLES ON ORGANOIDS DATA FOR CLINICAL TRIAL OUTCOMES AND MODELSFrom4 Apr 2025 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Towards a patient-centred market access of treatmentsFrom1 Oct 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- How to Sustain Market Access to Advanced Therapies? A Focus on Value Assessment and International Collaboration.From1 Oct 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Ethical, legal and social aspects of technologies for rare diseasesFrom22 Aug 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 233
- Evolution of Eligibility Criteria in Inflammatory Bowel Disease Clinical Trials: A Clinical Trial Databank Analysis(2025)Published in: United European gastroenterology journalISSN: 2050-6406Issue: 4Volume: 13Pages: 542 - 551
- Drawing on collective action theory to foster sustainable biosimilar markets - insights from co-creation workshops with UK and Belgian stakeholders(2025)Published in: Expert Opinion on Biological TherapyISSN: 1471-2598Issue: 4Volume: 25Pages: 437 - 446
- Non-clinical platform to predict exposure to maternal medicines via breastfeeding(2025)
- Information Service "My Cancer Navigator" to Support Shared Decision-Making: An Online Survey Among Patients with Cancer and Their Caregivers(2025)Published in: Journal of Health CommunicationISSN: 1081-0730Issue: 1-3Volume: 30Pages: 82 - 92
- Towards implementing new payment models for the reimbursement of high-cost, curative therapies in Europe: insights from semi-structured interviews(2025)Published in: Frontiers in PharmacologyISSN: 1663-9812Volume: 15
- Do European regulatory measures accelerate national market access in Belgium? A retrospective analysis of medicines centrally authorised between 2015 and 2020(2025)Published in: Bmj OpenISSN: 2044-6055Issue: 1Volume: 15
- Unmet medical needs definition and incentives: stakeholders perspectives on the reform of the EU pharmaceutical legislation(2025)Published in: Frontiers in MedicineISSN: 2296-858XVolume: 11
- Development and Characterization of a Human Mammary Epithelial Cell Culture Model for the Blood-Milk Barrier-A Contribution from the ConcePTION Project(2024)Published in: International Journal of Molecular SciencesISSN: 1661-6596Issue: 21Volume: 25
- Mitigating the Nocebo Effect in Biosimilar Use and Switching: A Systematic Review(2024)Published in: Pharmaceutical MedicineISSN: 1178-2595Issue: 6Volume: 38Pages: 429 - 455
- Heart failure patients' perspectives on treatment outcomes and unmet medical needs: A qualitative preference study(2024)Published in: ESC Heart FailureISSN: 2055-5822Issue: 5Volume: 11Pages: 2481 - +
Linked dataset
1 - 3 of 3
- Replication Data for: Public Perception and Willingness to Accept Somatic Gene Therapy: A Belgian Survey Study
- Bidirectional permeability of model medicines in an in vitro model based on primary culture of human (hMECs) or Göttingen minipig (mpMECs) mammary epithelial cells.
- Characterization of in vitro model based on primary culture of human mammary epithelial cells (hMECs): barrier integrity and functionality of transport routes.